Market Eyes LiveThe Cigna Group (CI) Stock Rating & Analysis
MELANY's data-driven read on The Cigna Group · Hospital & Medical Service Plans.
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy operations, substantially expanded by its 2018 merger with Express Scripts, are sold mostly to health insurance plans and employers. Its largest PBM contract is with the Department of Defense, and it recently won a multiyear deal with the major insurer Centene.
Why CI scores 60/100
MELANY scores The Cigna Group 60/100 by weighing eight factors. Here is how CI breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- P/E 11.5x vs sector 22.0x median
- PEG ratio 0.83 (< 1 = undervalued)
- FCF yield 10.8%
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
- Institutional net buying +10.7%
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for CI
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
The Cigna Group sits in the Healthcare sector theme, which MELANY currently rates 26/100 for strength. Theme strength feeds CI's momentum and catalyst factors above.
Tracking CI
The Cigna Group rates Hold right now, so MELANY is not flagging a fresh entry. Create a free account to add CI to your watchlist and get alerted the moment the rating changes.
How MELANY rates CI
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. The Cigna Group's 60/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about CI
Is The Cigna Group (CI) a buy?
As of 2026-08-13, MELANY rated The Cigna Group Hold with a composite score of 60/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is The Cigna Group's MELANY score?
The Cigna Group (CI) has a MELANY composite score of 60/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the CI stock rating calculated?
MELANY scores CI from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy The Cigna Group stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates The Cigna Group (CI) Hold with a composite of 60/100 as of 2026-08-13. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the CI stock price forecast?
MELANY does not publish price targets or forecasts for CI. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 60/100 across eight factors for The Cigna Group, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is CI stock overvalued or undervalued?
MELANY's valuation factor currently reads 86/100 for The Cigna Group, where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives CI's read.
What price should I buy CI at?
MELANY is not flagging a fresh entry for CI at its current Hold rating, so there is no entry zone to publish right now. Watchlisting CI in the free app gets you alerted the moment that changes.
What are the risks of buying CI stock?
The top risks MELANY currently flags for The Cigna Group: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is The Cigna Group a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 36/100 for The Cigna Group, and earnings track record, at 44/100. The 60/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will CI stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 53/100 for CI right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this CI rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-13. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores CI continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
CI's live rating and alerts are free either way. The app is our flagship.